AHA 2021 | AVATAR: Early Intervention in Asymptomatic Aortic Stenosis

Early surgical aortic valve replacement (SAVR) in patients with severe asymptomatic aortic stenosis can be beneficial in selected patients vs. waiting for symptoms. 

AHA 2021 | AVATAR: intervención precoz en estenosis aórtica asintomática

Severe AS in patients with no symptoms and conserved ventricular function raises few questions, clinically speaking. However, there is little evidence in favor of early intervention vs. close observation. 

The best data we had so far was brought by the RECOVERY study presented at that same meeting in 2019. With 145 patients randomized to early intervention vs. conventional strategy, this study found early SAVR in asymptomatic patients with severe aortic stenosis had lower risk of cardiovascular death at 6 years. 

The AVATAR included 157 patients between 2015 and 2020. Severe stenosis was defined as peak velocity > 4 m/seg, mean gradient > 40 mmHg and area < 1 cm2.

A mechanical valve was implanted in 53% of the 72 patients undergoing early SAVR (mean age 67).

Of all patients randomized to a conservative strategy, 25 required surgery: for symptom development (60%), stenosis progression (16%), ventricular function dropping below 50% (4%) or a combination of these factors (20%). Mean time from randomization to surgery was 400 días. 


Read also: TAVR vs Sutureless Surgical Aortic Valve Replacement in Low-Risk Patients.


After close to 3 years, the combined end point resulted 15.2% in the early intervention group vs 34.7% in the conservative group. All cause death and cardiac failure were responsible for tilting the scales in favor of early intervention. 

According to this study’s authors, the valve should be intervened when AS meets the severity criteria, regardless of symptoms.

AVATAR

Original Title: Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis.

Reference: Banovic M et al. Presentado en las sesiones científicas del congreso AHA 2021 y publicado simultáneamente en Circulation. 2021 Nov 13. Online ahead of print. doi: 10.1161/CIRCULATIONAHA.121.057639.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...